Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES versus DRIXORAL PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES versus DRIXORAL PLUS.
CHILDREN'S ZYRTEC HIVES vs DRIXORAL PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors, inhibiting histamine-mediated allergic reactions.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
5 mg or 10 mg orally once daily; maximum 10 mg/day.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 8-11 hours in healthy adults, allowing twice-daily dosing.
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
Cetirizine is primarily excreted renally (~60% unchanged), with ~10% fecal excretion.
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Category C
Category C
Antihistamine
Antihistamine/Decongestant